Preoperative Radiotherapy in Patients With Primary Retroperitoneal Sarcoma
Dario Callegaro(Fondazione IRCCS Istituto Nazionale dei Tumori), Alessandro Gronchi(Fondazione IRCCS Istituto Nazionale dei Tumori), Hans Gelderblom(Leiden University Medical Center), Rebecca A. Gladdy(Princess Margaret Cancer Centre), Rick L. Haas(Leiden University Medical Center), Deanna Ng(Mount Sinai Hospital), Chandrajit P. Raut(Dana-Farber Cancer Institute), Sylvie Bonvalot(Dana-Farber Cancer Institute), D. Strauß(Royal Marsden Hospital), Sandrine Marréaud(European Organisation for Research and Treatment of Cancer), Charles Honoré(Institut Gustave Roussy), Aisha Miah(Institute of Cancer Research), Claudia Sangalli(Fondazione IRCCS Istituto Nazionale dei Tumori), Winan J. van Houdt(Diakonessenhuis hospital), Piotr Rutkowski(The Maria Sklodowska-Curie National Research Institute of Oncology), Mark Fairweather(Brigham and Women's Hospital), Eberhard Stoeckle(Institut Bergonié), Saskia Litière(European Organisation for Research and Treatment of Cancer), Andrew Hayes(Royal Marsden NHS Foundation Trust), Peter Chung(Princess Margaret Cancer Centre), Taiwo Ajayi(European Organisation for Research and Treatment of Cancer), Elizabeth H. Baldini(Dana-Farber Cancer Institute), Dimitri Tzanis(Institut Curie), Magali Fau(University of Toronto), Carol J. Swallow(University Health Network)
Cited by 138
Related Papers
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k
Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2012|3k
Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial
|The Lancet|2012|2.1k
Cremophor EL
|European Journal of Cancer|2001|1.6k